Target intelligence / Profile preview

Hepatocyte apoptosis

Molecular classification
Other (biological process, not a molecule), Programmed cell death
01

Overview

Hepatocyte apoptosis is the tightly regulated process of programmed cell death that occurs in liver cells. It plays a critical role in maintaining liver homeostasis, removing damaged or infected cells, and modulating immune responses. Apoptosis in hepatocytes can be initiated via the extrinsic (death receptor–mediated) pathway, involving molecules like Fas receptor, TNF-receptor, and TRAIL receptor, or the intrinsic (mitochondrial) pathway, involving mitochondrial outer membrane permeabilization and release of factors like cytochrome c. Dysregulation of hepatocyte apoptosis is implicated in the pathogenesis and progression of various liver diseases, including viral hepatitis, nonalcoholic fatty liver disease (NAFLD), fibrosis, cirrhosis, and hepatocellular carcinoma. While apoptosis is not a druggable target itself, the molecular components of its signaling pathways (e.g., caspases, death receptors, Bcl-2 family proteins) are under investigation as potential therapeutic targets to modulate liver disease outcomes.

Other names
Hepatocyte cell deathliver cell apoptosisprogrammed death of hepatocytes
02

Mechanism of action

Inhibition of caspases to prevent apoptosis; Activation or blockade of death receptor signaling (Fas, TRAIL, TNF-α pathways); Mitochondrial/intrinsic pathway modulation (Bcl-2 family, cytochrome c release)

03

Biological functions

Cell deathTissue homeostasisElimination of damaged or infected cellsInflammation regulation
04

Disease associations

Liver disease progression (e.g., hepatitis, liver fibrosis, acute liver failure)Cancer (e.g., hepatocellular carcinoma)InflammationMetabolic diseases (e.g., NAFLD)
05

Safety considerations

Complete inhibition of apoptosis can lead to necrosis or necroptosis, sometimes worsening liver injuryBlocking apoptosis may increase cancer risk, while excessive apoptosis can cause acute liver failureCaspase inhibitors may have off-target or systemic effects
06

Interacting drugs

Caspase inhibitors (e.g., z-VAD-fmk)

3 more in the full profile.

07

Biomarkers

Cleaved caspase-3Cleaved PARP1Bax/Bcl2 ratioSerum markers of cell death (ALT/AST in clinical contexts)

Beyond the preview

Go deeper on Hepatocyte apoptosis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatocyte apoptosis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call